FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3204172404> ?p ?o ?g. }

• W3204172404 endingPage "e471" @default.
• W3204172404 startingPage "e470" @default.
• W3204172404 abstract "Purpose/Objective(s)Clinical outcomes for limited stage small cell lung cancer (LS-SCLC) remain suboptimal. Standard of care chemoradiation with platinum/etoposide and thoracic radiation to 45 Gy delivered twice daily followed by prophylactic cranial irradiation yields a median overall survival of 30 months. LU005 is a randomized phase II/III trial designed to test the addition of atezolizumab to concurrent chemoradiation.Materials/MethodsPatients with LS-SCLC (Tx-T4, N0-N3, M0) are randomly assigned in a 1:1 ratio to either standard chemoradiation, consisting of thoracic radiation (45 Gy twice daily or 66 Gy daily) with concurrent platinum/etoposide chemotherapy, or the experimental arm, consisting of the same chemoradiation regimen plus the addition of atezolizumab delivered concurrently with thoracic radiation, every 3 weeks for 12 months duration. Thoracic radiation begins with the second cycle of chemotherapy in both treatment arms. Stratification variables include radiation schedule (once daily vs. twice daily), chemotherapy (cisplatin vs. carboplatin), gender, and performance status (PS 0/1 vs. 2). Prophylactic cranial radiation is recommended for patients who have a response to treatment. The phase II primary endpoint is progression free survival (PFS) and the phase III primary endpoint is overall survival (OS). The overall sample size for phase II/III will be 506. Secondary endpoints include objective response rates, local control, distant metastases free, and quality of life. Correlative studies will include blood and tissue based tumor mutational burden analysis, with the hypothesis that higher mutational burden will predict for improved PFS in the experimental arm.ResultsAs of 3/01/2021, 374 sites are approved to enroll patients. Two-hundred patients have been accrued. Current enrollment is ahead of projected accrual.ConclusionLU005 is a randomized II/III trial testing the addition of atezolizumab to standard chemoradiation for LS-SCLC. Accrual remains robust in spite of the ongoing COVID 19 pandemic. Funding: This project was supported by grants U10CA180868 (NRG Oncology Operations), U10CA180822 (NRG Oncology SDMC), U24CA180803 (IROC) from the National Cancer Institute (NCI) and Genentech. Clinical outcomes for limited stage small cell lung cancer (LS-SCLC) remain suboptimal. Standard of care chemoradiation with platinum/etoposide and thoracic radiation to 45 Gy delivered twice daily followed by prophylactic cranial irradiation yields a median overall survival of 30 months. LU005 is a randomized phase II/III trial designed to test the addition of atezolizumab to concurrent chemoradiation. Patients with LS-SCLC (Tx-T4, N0-N3, M0) are randomly assigned in a 1:1 ratio to either standard chemoradiation, consisting of thoracic radiation (45 Gy twice daily or 66 Gy daily) with concurrent platinum/etoposide chemotherapy, or the experimental arm, consisting of the same chemoradiation regimen plus the addition of atezolizumab delivered concurrently with thoracic radiation, every 3 weeks for 12 months duration. Thoracic radiation begins with the second cycle of chemotherapy in both treatment arms. Stratification variables include radiation schedule (once daily vs. twice daily), chemotherapy (cisplatin vs. carboplatin), gender, and performance status (PS 0/1 vs. 2). Prophylactic cranial radiation is recommended for patients who have a response to treatment. The phase II primary endpoint is progression free survival (PFS) and the phase III primary endpoint is overall survival (OS). The overall sample size for phase II/III will be 506. Secondary endpoints include objective response rates, local control, distant metastases free, and quality of life. Correlative studies will include blood and tissue based tumor mutational burden analysis, with the hypothesis that higher mutational burden will predict for improved PFS in the experimental arm. As of 3/01/2021, 374 sites are approved to enroll patients. Two-hundred patients have been accrued. Current enrollment is ahead of projected accrual. LU005 is a randomized II/III trial testing the addition of atezolizumab to standard chemoradiation for LS-SCLC. Accrual remains robust in spite of the ongoing COVID 19 pandemic. Funding: This project was supported by grants U10CA180868 (NRG Oncology Operations), U10CA180822 (NRG Oncology SDMC), U24CA180803 (IROC) from the National Cancer Institute (NCI) and Genentech." @default.
• W3204172404 created "2021-10-11" @default.
• W3204172404 creator A5004625690 @default.
• W3204172404 creator A5005668744 @default.
• W3204172404 creator A5014554706 @default.
• W3204172404 creator A5015060656 @default.
• W3204172404 creator A5020215408 @default.
• W3204172404 creator A5030249492 @default.
• W3204172404 creator A5032192226 @default.
• W3204172404 creator A5040079785 @default.
• W3204172404 creator A5057216643 @default.
• W3204172404 creator A5065305886 @default.
• W3204172404 creator A5069565044 @default.
• W3204172404 creator A5075890039 @default.
• W3204172404 creator A5080256711 @default.
• W3204172404 creator A5080385781 @default.
• W3204172404 creator A5084575406 @default.
• W3204172404 creator A5085763839 @default.
• W3204172404 date "2021-11-01" @default.
• W3204172404 modified "2023-10-13" @default.
• W3204172404 title "NRG Oncology/Alliance LU005: A Phase II/III Randomized Study of Chemoradiation vs. Chemoradiation Plus Atezolizumab in Limited Stage Small Cell Lung Cancer" @default.
• W3204172404 doi "https://doi.org/10.1016/j.ijrobp.2021.07.1312" @default.
• W3204172404 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34701531" @default.
• W3204172404 hasPublicationYear "2021" @default.
• W3204172404 type Work @default.
• W3204172404 sameAs 3204172404 @default.
• W3204172404 citedByCount "2" @default.
• W3204172404 countsByYear W32041724042023 @default.
• W3204172404 crossrefType "journal-article" @default.
• W3204172404 hasAuthorship W3204172404A5004625690 @default.
• W3204172404 hasAuthorship W3204172404A5005668744 @default.
• W3204172404 hasAuthorship W3204172404A5014554706 @default.
• W3204172404 hasAuthorship W3204172404A5015060656 @default.
• W3204172404 hasAuthorship W3204172404A5020215408 @default.
• W3204172404 hasAuthorship W3204172404A5030249492 @default.
• W3204172404 hasAuthorship W3204172404A5032192226 @default.
• W3204172404 hasAuthorship W3204172404A5040079785 @default.
• W3204172404 hasAuthorship W3204172404A5057216643 @default.
• W3204172404 hasAuthorship W3204172404A5065305886 @default.
• W3204172404 hasAuthorship W3204172404A5069565044 @default.
• W3204172404 hasAuthorship W3204172404A5075890039 @default.
• W3204172404 hasAuthorship W3204172404A5080256711 @default.
• W3204172404 hasAuthorship W3204172404A5080385781 @default.
• W3204172404 hasAuthorship W3204172404A5084575406 @default.
• W3204172404 hasAuthorship W3204172404A5085763839 @default.
• W3204172404 hasBestOaLocation W32041724041 @default.
• W3204172404 hasConcept C121608353 @default.
• W3204172404 hasConcept C126322002 @default.
• W3204172404 hasConcept C143998085 @default.
• W3204172404 hasConcept C168563851 @default.
• W3204172404 hasConcept C203092338 @default.
• W3204172404 hasConcept C2775949291 @default.
• W3204172404 hasConcept C2776256026 @default.
• W3204172404 hasConcept C2776694085 @default.
• W3204172404 hasConcept C2777701055 @default.
• W3204172404 hasConcept C2778119113 @default.
• W3204172404 hasConcept C2778239845 @default.
• W3204172404 hasConcept C2778336483 @default.
• W3204172404 hasConcept C2779562246 @default.
• W3204172404 hasConcept C2780057760 @default.
• W3204172404 hasConcept C2781413609 @default.
• W3204172404 hasConcept C2781451048 @default.
• W3204172404 hasConcept C31760486 @default.
• W3204172404 hasConcept C45393284 @default.
• W3204172404 hasConcept C500558357 @default.
• W3204172404 hasConcept C509974204 @default.
• W3204172404 hasConcept C71924100 @default.
• W3204172404 hasConceptScore W3204172404C121608353 @default.
• W3204172404 hasConceptScore W3204172404C126322002 @default.
• W3204172404 hasConceptScore W3204172404C143998085 @default.
• W3204172404 hasConceptScore W3204172404C168563851 @default.
• W3204172404 hasConceptScore W3204172404C203092338 @default.
• W3204172404 hasConceptScore W3204172404C2775949291 @default.
• W3204172404 hasConceptScore W3204172404C2776256026 @default.
• W3204172404 hasConceptScore W3204172404C2776694085 @default.
• W3204172404 hasConceptScore W3204172404C2777701055 @default.
• W3204172404 hasConceptScore W3204172404C2778119113 @default.
• W3204172404 hasConceptScore W3204172404C2778239845 @default.
• W3204172404 hasConceptScore W3204172404C2778336483 @default.
• W3204172404 hasConceptScore W3204172404C2779562246 @default.
• W3204172404 hasConceptScore W3204172404C2780057760 @default.
• W3204172404 hasConceptScore W3204172404C2781413609 @default.
• W3204172404 hasConceptScore W3204172404C2781451048 @default.
• W3204172404 hasConceptScore W3204172404C31760486 @default.
• W3204172404 hasConceptScore W3204172404C45393284 @default.
• W3204172404 hasConceptScore W3204172404C500558357 @default.
• W3204172404 hasConceptScore W3204172404C509974204 @default.
• W3204172404 hasConceptScore W3204172404C71924100 @default.
• W3204172404 hasIssue "3" @default.
• W3204172404 hasLocation W32041724041 @default.
• W3204172404 hasLocation W32041724042 @default.
• W3204172404 hasOpenAccess W3204172404 @default.
• W3204172404 hasPrimaryLocation W32041724041 @default.
• W3204172404 hasRelatedWork W1847381023 @default.
• W3204172404 hasRelatedWork W1989051367 @default.
• W3204172404 hasRelatedWork W1995323461 @default.
• W3204172404 hasRelatedWork W2029688276 @default.
• W3204172404 hasRelatedWork W2170498496 @default.

• next